Gastroenterology

Search

All France Foundation Content

Results 1 - 31 of 31

New Frontiers in the Treatment of DMD Across the Age Spectrum

Expanding DMD Treatment Horizons: New Evidence

New Frontiers in the Treatment of DMD Across the Age Spectrum

Strides for DMD–Advancing Therapies, Empowering Patients Microlearning Library

Advances in the Unmet Needs of Myotonic Dystrophy Type 1 (DM1)

Addressing the Unmet Needs of Myotonic Dystrophy Type 1 (DM1)

Slide Download: Diagnosis, Assessment, and Therapeutic Management of BTC

Advances in the Diagnosis, Assessment, and Therapeutic Management of BTC

Hereditary Transthyretin Amyloidosis: Case Studies

hATTR Amyloidosis: You and Your Family

sma-journal-icon_263x0

Gene Therapy for SMA: An Emerging Treatment Option for a Devastating Disease

SMA: Data, Insights and Practice

From Bench to Bedside: Gene Therapy Approaches for Rare Diseases

What’s New in Spinal Muscular Atrophy? Reporting from Dallas

SMA Updates from Los Angeles

Updates in SMA and Gene Therapy from Arlington, VA

biosims-archmed icon1

Top Questions about Biosimilars in Gastroenterology

biosims-gastro2

Biosimilars and Patients with Inflammatory Bowel Disease

biosims-gastro1

Biosimilars: The New Era of Gastroenterology Management Considerations

IL-gastro-case3

Ulcerative Colitis: What Can You Expect When a Patient is Switched to a Biosimilar?

IL-gastro-case2

Biosimilars in Patients with Crohn’s Disease Failing an Initial Biologic

IL-gastro-case1

Innovator or Biosimilar for a Patient with Ulcerative Colitis?

Interchangeability and Pharmacy-Level Substitution

FDA Criteria: Biosimilar Approval, Manufacturing, & Naming

What is the Difference Between a Biosimilar and a Generic?

What is a Biologic?

Sorting it Out: Biologics, Biosimilars, Small Molecule Drugs, and Generics

Health Care Providers’ Perspectives on Biosimilars: Based in Fact or Not?

Pharmacovigilance and Biosimilars: Any Special Considerations?

Interchangeability and Biosimilars: What will this Mean for Clinical Practice?

Can a Biosimilar be Used for the Same Indications Approved for the Reference Biologic?

Biosimilars: As Safe and Effective as the Reference Product?

Drift and the Manufacturing of Biologics: What is it and Does it Matter?

Biosimilars in Clinical Practice: Interchangeability and Extrapolation

The France Foundation

A ACCME Accredited provider.

The France Foundation ©

10 Vista Drive, Old Lyme, CT USA